The added value of chemotherapy after secondary cytoreductive surgery in unifocal versus multifocal first recurrent epithelial ovarian cancer: A systematic review.

ABSTRACT:

Objective

This systematic review aims to evaluate the added value of chemotherapy after secondary cytoreductive surgery (SCS) on survival in patients with unifocal and multifocal first recurrent epithelial ovarian cancer (EOC). Moreover, it compares survival outcomes between unifocal and multifocal recurrences in treatment outcomes.

Methods

A systematic search was conducted across PubMed, Embase, and the Cochrane Library identified 907 articles. Studies were selected if they involved patients with first recurrent EOC undergoing SCS, stratified by unifocal or multifocal recurrence. The primary outcomes were progression-free survival (PFS) and overall survival (OS).

Results

No studies specifically addressed the added value of chemotherapy after SCS in unifocal versus mu

SUBMITTER: van de Vorst REWM 

PROVIDER: S-EPMC12320076 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature